Carcinoid heart disease

Article written and reviewed by Dr Luca Moretti

Carcinoid heart disease is the fibrosing cardiovascular manifestation of carcinoid syndrome associated with secreting neuroendocrine neoplasms. The typical target is the endocardium of the right heart: the tricuspid leaflets and pulmonary cusps become thickened, retracted and progressively immobile, producing mainly regurgitation, sometimes stenosis and often a combination of the two. The final result is right ventricular overload that can progress to systemic congestion, organ dysfunction and severe functional limitation.

Cardiac disease is not synonymous with the mere presence of a neuroendocrine tumor. It requires biologically relevant amounts of serotonin and other mediators to reach the systemic circulation, which frequently occurs when an enteric neoplasm has metastasized to the liver and secretion bypasses first-pass hepatic degradation. Bronchial or ovarian tumors can cause systemic exposure even without liver metastases. The intensity and duration of exposure contribute to risk, but by themselves do not predict the phenotype of an individual patient.

Management belongs simultaneously to valvular cardiology, oncology, endocrinology, cardiac surgery, hepatology and anesthesia. Controlling hormonal secretion does not restore mobility to already fibrotic leaflets; correcting the valves without stabilizing the syndrome as much as possible instead exposes the patient to progression and perioperative complications. The decision therefore cannot be reduced either to echocardiographic severity or to oncologic stage considered in isolation.

Early recognition is crucial because symptoms may be attributed to diarrhea, malnutrition, liver metastases or antineoplastic treatment while the right ventricle continues to remodel. Biomarkers and serial echocardiography aim to detect this phase. Once heart disease has been documented, the pathway must distinguish hormonal activity, anatomic extent, hemodynamic severity, right-heart reserve and the real possibility that an intervention will improve quality and length of life.

Pathogenesis, pathology and valvular distribution

Serotonin, or 5-hydroxytryptamine, is the mediator most closely associated with valvular fibrosis. Activation of 5-HT2B receptors on interstitial cells and myofibroblasts promotes proliferation, extracellular matrix synthesis and collagen deposition. Tachykinins, prostaglandins, histamine, bradykinin and growth factors may modulate the process. It is therefore correct to speak of serotonergic pathogenesis, provided that a strong biological association is not turned into an exclusive explanation for a heterogeneous disease.

The macroscopic lesions are smooth, whitish plaques deposited on endocardial surfaces and composed of myofibroblasts, smooth muscle cells, collagen and mucopolysaccharide matrix. Unlike endocarditis, they do not primarily destroy tissue through vegetations and perforations; unlike rheumatic disease, commissural fusion and organized chronic inflammation do not predominate. The plaque coats the valvular surface, chordae, right-sided chambers and sometimes the intima of the great vessels, entrapping structures that otherwise remain recognizable.

In the tricuspid valve, thickening and shortening of the leaflets and subvalvular apparatus prevent systolic coaptation. The valve remains in a semi-open position, with a broad regurgitant orifice and sometimes an additional diastolic gradient. This anatomy produces primary tricuspid regurgitation, distinct from secondary forms in which initially normal leaflets are separated by annular dilatation and tethering. In advanced stages the two components may coexist.

The pulmonary valve is frequently involved but may be underestimated because it is more difficult to visualize. Thickened, retracted and hypomobile cusps cause pulmonary regurgitation; annular retraction or cusp rigidity adds stenosis. Combined tricuspid and pulmonary regurgitation subjects the right ventricle to volume overload during both phases of the cardiac cycle, which explains why correcting the tricuspid valve alone may leave a substantial residual burden.

The prevalence of left-sided involvement varies by population and imaging method, but remains markedly lower than right-sided involvement. The lungs metabolize some of the mediators through monoamine oxidase; the mitral and aortic valves become more vulnerable in the presence of a right-to-left shunt, a bronchial neuroendocrine tumor or a very high and persistent secretory burden. A left-sided lesion, however, should not automatically be attributed to carcinoid disease: degeneration, ischemia, endocarditis and radiotherapy are common alternatives.

The myocardium may contain metastases, whereas the pericardium, coronary arteries and nonvalvular endocardium may be involved more rarely. Cardiac metastases are an anatomic oncologic problem and are not synonymous with mediator-induced valvular heart disease. The distinction guides imaging and treatment: a mass requires tissue and receptor characterization, whereas diffuse plaques with retracted valves require hemodynamic assessment. Both manifestations can coexist in the same patient.

The fibrotic process tends to progress as long as exposure continues, but its rate is not uniform. High 5-HIAA concentrations, long duration of the syndrome and poor biochemical control are associated with a greater probability of disease or progression without constituting a deterministic relationship. Even when levels fall after treatment, an established plaque may continue to have hemodynamic consequences because of permanent deformation of the valve.

The anatomic phenotype explains why repair is often less reproducible than replacement. The tissue is diffusely retracted, the chordae are shortened and multiple leaflets may be immobile; reducing annular size does not correct a lack of mobile leaflet area and may increase stenosis. Repair is possible only in exceptionally favorable anatomy and when credible durability is expected, not as an automatic application of the general principle of valve preservation.

Clinical manifestations, biomarkers and screening program

Carcinoid syndrome classically presents with flushing, secretory diarrhea, bronchospasm and vasomotor fluctuations, but expression varies with tumor site and secretory profile. Cardiac signs may appear after years or may be recognized when the syndrome is already advanced. Fatigue, dyspnea, edema, abdominal distension and weight loss are nonspecific and overlap with treatment toxicity, malabsorption and tumor progression.

Tricuspid regurgitation causes prominent systolic venous waves, a pulsatile liver, ascites and edema; the murmur may increase with inspiration but may become faint when right atrial and ventricular pressures equalize rapidly. A stenotic component produces a diastolic rumble and worsens atrial congestion. Pulmonary valve disease adds a diastolic or systolic murmur, often difficult to distinguish in a chest with multiple acoustic phenomena and low output.

The right ventricle initially compensates for the volume load through dilatation and increased total stroke volume. Later, wall stress rises, contractile reserve declines and forward output becomes inadequate. Hepatic congestion and metastases can both cause ascites, coagulation abnormalities and hypoalbuminemia; identifying the cardiac contribution is essential because it may be reversible after valve correction, whereas advanced liver damage increases operative risk.

The 24-hour urinary metabolite 5-HIAA documents serotonin production and helps monitor secretory control. Diet, medications, renal function and incomplete collection cause interference; plasma and urine measurements are not interchangeable without laboratory-validated methods and reference ranges. A high value supports increased risk but does not directly measure the degree of regurgitation, right ventricular function or surgical candidacy.

NT-proBNP reflects wall stress and is useful as a selection test in the appropriate context. The ENETS document indicates that, in patients with carcinoid syndrome or high 5-HIAA exposure, a value above 260 pg/mL should prompt echocardiography; however, this is not a universal diagnostic or exclusion threshold. In a contemporary cohort, sensitivity at that cutoff was only 46%, confirming that a lower value does not exclude early disease. Age, atrial fibrillation, renal function and other cardiac diseases also affect the concentration.

Combined screening begins by identifying patients at risk rather than indiscriminately performing echocardiography in every neuroendocrine neoplasm. Carcinoid syndrome, markedly elevated 5-HIAA, NT-proBNP above threshold, a murmur or signs of congestion warrant cardiologic assessment. ENETS recommendations indicate baseline echocardiographic assessment and surveillance generally every six to twelve months in patients with carcinoid syndrome or documented heart disease, adjusted according to the clinical picture, biomarkers, secretory activity and previous findings; biochemical checks every three to six months mainly belong to postoperative follow-up or selected conditions rather than constituting a universal schedule for every at-risk phenotype.

A single normal echocardiogram does not end surveillance if substantial secretion persists. The disease can develop or progress over a relatively short period; a baseline examination and standardized comparisons are therefore necessary. Conversely, repeating noncomparable imaging too frequently creates noise. A shared protocol records the morphology of each leaflet or cusp, severity of stenosis and regurgitation, right-sided chamber size and function, and the presence of shunts.

Clinical assessment should include blood pressure, rhythm, volume status, functional class, weight, nutritional status, and renal and hepatic function. The electrocardiogram and chest radiograph are nonspecific but can document arrhythmias, effusions or cardiomegaly. Atrial fibrillation can worsen cardiac output, whereas a patent foramen ovale with elevated right-sided pressures may cause hypoxemia and simultaneously expose the left-sided valves to circulating mediators.

Serial changes in NT-proBNP, 5-HIAA and echocardiographic findings are more informative than isolated crossing of a threshold. An increase in natriuretic peptide together with progressive right ventricular dilatation may precede overt symptoms; rising 5-HIAA signals the need to reassess oncologic control and fibrotic risk. Procedural decisions, however, always require integrated assessment of anatomy, hemodynamics, cardiac reserve and oncologic prognosis.

Echocardiography, multimodality imaging and definition of severity

Transthoracic echocardiography is the cornerstone examination and should assess the tricuspid, pulmonary, mitral and aortic valves separately, avoiding the tendency for very prominent tricuspid regurgitation to overshadow pulmonary valve disease. For each leaflet or cusp, thickness, retraction, excursion and coaptation should be described; Doppler, chamber dimensions and venous consequences then complete the assessment of each lesion. A synoptic report based on the ENETS scheme facilitates serial comparison and reduces the risk of omissions.

In advanced tricuspid disease, short and immobile leaflets remain semi-open. Color Doppler shows broad regurgitation, while continuous-wave Doppler may be dense, triangular and low velocity because of rapid pressure equalization. Vena contracta, systolic hepatic vein flow reversal, flow convergence and right-sided dilatation are integrated; PISA may underestimate a noncircular orifice and should not be the sole criterion.

Associated tricuspid stenosis requires assessment of the mean gradient at a known heart rate, morphology and flow. The high diastolic flow generated by regurgitation itself can increase the gradient without a proportional anatomic reduction in the orifice. Conversely, low cardiac output can mask obstruction. Carcinoid heart disease is therefore an example in which stenosis and regurgitation must be classified separately, but their interaction determines the actual hemodynamic burden.

Assessment of the pulmonary valve requires multiple windows because visualization of the cusps and right ventricular outflow tract may be incomplete. Stenosis is assessed from velocity and gradient while accounting for flow, whereas regurgitation assessment integrates jet width, signal density and deceleration, flow in the pulmonary arteries and ventricular dimensions. A cusp that is not visualized cannot be considered normal; 3D and transesophageal echocardiography may add anatomic information, although both remain limited by the anterior position of the valve.

Right ventricular function is assessed multiparametrically using dimensions, fractional area change, TAPSE, S′ velocity, strain and, when available, 3D ejection fraction. Every measure is load dependent and no single threshold defines irreversibility. A markedly dilated ventricle may retain apparently preserved longitudinal excursion, whereas elimination of regurgitation increases effective afterload and may reveal reduced contractile reserve.

Cardiac magnetic resonance imaging provides highly reproducible right ventricular volumes and ejection fraction, quantifies pulmonary flows and identifies myocardial masses. It is particularly useful when echocardiographic windows, multiple jets or ventricular geometry produce discordant data. It does not replace high-resolution visualization of thin valve leaflets, but complements assessment of chamber damage and the metastatic component.

Cardiac CT defines valves, annuli, coronary arteries, calcification, the relationship with the sternum and anatomy for a surgical or transcatheter procedure. Oncologic CT and receptor imaging with radiolabeled somatostatin analogues localize primary and metastatic disease. Myocardial uptake requires anatomic correlation: receptor activity demonstrates neuroendocrine tissue, not the serotonergic nature of a valve dysfunction.

Right-heart catheterization is not routine in every patient but is useful when severity, output and pressures are unclear or when procedural risk depends on hemodynamics. Massive tricuspid regurgitation produces large v waves and may make thermodilution inaccurate; the Fick method in turn has limitations when oxygen consumption is estimated. Invasive pressures should answer a defined clinical question and do not substitute for incomplete imaging.

Overall severity includes valve dysfunction, remodeling, symptoms and congestion. Moderate lesions of both right-sided valves may impose a major burden; severe tricuspid disease with a still-adapted ventricle is not biologically benign. Conversely, ascites in the presence of liver metastases does not by itself prove terminal heart failure. The integrated profile guides timing and the likelihood of recovery.

The main differential diagnoses are secondary tricuspid regurgitation, endocarditis, rheumatic disease, serotonergic drug-induced valvular disease, endomyocardial fibrosis and radiation injury. Right-sided distribution and carcinoid syndrome are suggestive, but treatment history and morphology remain necessary. A patient with a neuroendocrine tumor may also have degenerative aortic stenosis or ischemic mitral regurgitation, which require independent reasoning.

Neuroendocrine control, heart failure and perioperative management

Therapy must address hormonal secretion, tumor burden and cardiac consequences at the same time. Somatostatin analogues are the foundation of symptomatic control of carcinoid syndrome and can reduce circulating mediators, whereas telotristat, by inhibiting peripheral serotonin synthesis, is used mainly for refractory diarrhea in selected patients. These treatments, however, have not been shown to reverse established valvular plaques or to reliably prevent progression of heart disease.

Resection, embolization or other liver-directed therapies, peptide receptor radionuclide therapy and systemic treatments are selected according to tumor site, grade, receptor expression, extent and trajectory. Reducing secretory burden is desirable before and after cardiac intervention, but the sequence is not universal. Severe right-sided heart failure may make a hepatic procedure hazardous; valve correction may instead create the conditions for more effective oncologic treatment.

Control of congestion requires cautious diuresis. Loop diuretics reduce edema and ascites and, when needed, may be combined with mineralocorticoid receptor antagonists or used in a sequential strategy, while always monitoring blood pressure, renal function and electrolytes. In a low-output patient, excessive preload depletion may worsen renal perfusion; paracentesis and hepatology support are therefore incorporated when indicated. Medical therapy remains a bridge or a palliative component and does not correct the fibrotic valve.

Before a procedure, systemic frailty should also be considered, often driven by malnutrition, diarrhea, niacin deficiency, anemia and hypoalbuminemia. Preparation includes nutritional assessment, correction of imbalances, dental health and a search for infection; abnormal liver function may also reflect metastases, congestion or both, and distinguishing their contribution helps estimate bleeding risk and reversibility. Multidisciplinary discussion should therefore avoid both automatic exclusion and unrealistic expectations.

Carcinoid crisis is a perioperative syndrome of hemodynamic instability, flushing, bronchospasm and massive mediator release, potentially triggered by anesthesia, tumor manipulation, hypotension or stress. A uniform definition has been lacking in many studies, making incidence uncertain and protocols difficult to compare. In patients undergoing cardiac surgery, the combination with right-sided dysfunction and cardiopulmonary bypass amplifies the consequences.

Short-acting somatostatin analogues are traditionally administered before, during and after high-risk procedures, with immediate availability of boluses and infusion. ENETS and expert centers propose regimens, but dose and duration are not supported by robust randomized trials. A meta-analysis did not demonstrate that octreotide prophylaxis, applied through heterogeneous protocols, eliminates the risk. The correct formulation is therefore mandatory preparation according to an expert protocol, not a pharmacologic guarantee.

The anesthesiologist plans invasive monitoring, access to vasoactive drugs and crisis management without relying on octreotide alone. Hypotension may result from mediator-induced vasodilation, low output, bleeding or vasoplegia from cardiopulmonary bypass; indiscriminate treatment is hazardous. Coordination with the endocrinologist and surgeon, availability of transesophageal echocardiography and rapid correction of the cause are more important than any single recipe.

Oncologic control continues after valve replacement. Persistently high mediator levels expose residual tissue and bioprostheses to new plaques, although documented recurrence is less frequent than once feared. Biomarkers and oncologic imaging are coordinated with cardiologic follow-up; improvement in congestive symptoms should not be interpreted as remission of the neoplasm or secretory syndrome.

Valve surgery, transcatheter options and follow-up

Surgery is the only established treatment capable of eliminating the obstruction and regurgitation produced by irreversibly retracted leaflets. It is considered mainly in symptomatic severe valve dysfunction or when cardiac correction may make oncologic therapy feasible, provided that the neoplasm, comorbidities and organ reserve make durable benefit plausible. In an asymptomatic patient, progressive right ventricular dilatation or dysfunction requires close surveillance and individual discussion, but dilatation alone is not in itself a surgical indication. Waiting until cachexia, severe renal or hepatic failure and advanced ventricular dysfunction markedly increases risk.

Selection for intervention cannot be reduced to a single oncologic threshold. ENETS regards an expected survival of at least approximately one year and a sufficiently controllable tumor as favorable, but this is a probabilistic estimate that must be integrated with quality of life, tumor trajectory, remaining options, severity of heart failure and patient preferences. Limited life expectancy does not automatically negate a possible symptomatic benefit, but changes its proportions and goals.

Tricuspid valve replacement is the most common procedure and, when possible, preservation of the subvalvular apparatus helps maintain ventricular geometry provided diseased tissue does not interfere with the prosthesis. Repair is uncommon because of diffuse fibrosis. Because the operation carries a risk of atrioventricular block, the need for pacing should be anticipated and, if pacing is required, strategies that avoid a transvalvular lead capable of damaging or obstructing the prosthesis are preferred.

When the pulmonary valve is also significantly involved, treating it during the same operation reduces residual regurgitation and right ventricular volume overload. Valvectomy without prosthetic replacement, used historically, may promote progressive dilatation, and in stenotic anatomy the outflow tract may need enlargement with a patch. The mitral and aortic valves should instead be corrected only when the left-sided lesion is truly attributable to the disease and clinically significant, not merely because of minimal thickening.

Bioprostheses are generally preferred in the right heart because they are less thrombogenic than mechanical prostheses and avoid permanent anticoagulation in patients with liver metastases or invasive procedures. They are not immune to thrombosis, degeneration or carcinoid deposition. Young age, long oncologic life expectancy and independent indications for anticoagulation may alter the choice. The antithrombotic plan follows prosthesis type and position, rhythm, bleeding risk and valvular guidelines.

Contemporary series show a substantial reduction in operative mortality compared with early experience and frequent improvement in symptoms and functional capacity. They remain observational studies from expert centers, with candidate selection and no randomized proof of a survival benefit. Late mortality often depends on tumor progression; attributing a direct oncologic effect to surgery would be incorrect.

Transcatheter interventions are reserved for selected cases with prohibitive surgical risk, especially valve-in-valve procedures for degenerated bioprostheses or, more rarely, native tricuspid replacement. Fibrotic and stenotic anatomy may be unfavorable for edge-to-edge repair, which requires graspable tissue and a manageable coaptation gap. Evidence specific to carcinoid disease comes from case reports and small series and cannot be automatically extrapolated from trials of secondary tricuspid regurgitation.

Before discharge, a prosthetic baseline is obtained including gradients, regurgitation, biventricular function and venous pressure. Early follow-up assesses congestion, rhythm, wound healing, anticoagulation and secretory control. Thereafter, echocardiography, NT-proBNP and 5-HIAA are scheduled according to residual severity, syndrome activity and prosthesis type. An early rise in gradient requires distinction among high flow, thrombosis, mismatch and degeneration.

Follow-up maintains a dual perspective. On the cardiac side it monitors prostheses, the right ventricle, untreated valves and heart failure; on the neuroendocrine side it assesses secretion, tumor burden, nutrition and treatment options. The patient should understand that replacement improves hemodynamics but does not cure the tumor, while biochemical control reduces exposure without repairing an already deformed valve.

Carcinoid heart disease becomes treatable when it is identified before irreversible damage and described in a common language shared by specialists. Targeted screening, structured echocardiographic reporting, mediator control and timely selection for intervention are parts of the same pathway. The quality of the decision depends less on a single threshold than on the ability to recognize the combined trajectory of the neoplasm, the valves and the right ventricle.